Vaginal Probiotic Product Reduces Recurrence Rate of Bacterial Vaginosis

The Danish company Bifodan A/S has announced that a newly published double blind, randomised, placebo controlled study shows that EcoVag, a patented vaginal probiotic product, significantly reduces the recurrence rate of Bacterial Vaginosis, BV, following antibiotic treatment. BV is one of the most frequent vaginal infections and if left untreated may have severe gynaecological and obstetric consequences such as pelvic inflammatory disease, miscarriage and preterm delivery.

The study involved 100 women diagnosed with BV. All women were given a standard antibiotic treatment with Clindamycin vaginal cream. On a randomised basis half of the cured women were treated with one EcoVag vaginal capsule and the other half with an identical placebo capsule per day for 10 days during 3 consecutive menstrual cycles to measure the impact on recurrent infection rates. The study shows that the recurrent BV infection rate is significantly reduced for the women taking EcoVag. At the study completion after 6 months, 65% of the EcoVag treated women were still BVfree compared to 46% of the placebo treated women. Comparison of the two groups regarding "time from cure to relapse" was also statistically significant. Furthermore, the study also confirmed that EcoVag is safe to use.

For further information please contact:

Niels Peter Bak

Business Development Manager

Tel: +45 47 98 15 16

Email: npb@bifodan.com

Or visit: www.bifodan.com